Cocrystal Pharma, Inc. (COCP) Form 8-K — Jun 9, 2026
Cocrystal Pharma appointed James Sapirstein as Chief Executive Officer effective June 3, 2026, replacing the previous co-CEO structure held by Sam Lee and James Martin. Sapirstein, formerly CEO of Entero Therapeutics, brings significant biopharmaceutical leadership experience to the role. The compensation package includes a $265,000 annual base salary, a 50% performance bonus target, and an initial grant of 235,000 stock options exercisable at $1.05. An additional 235,000 options may be granted after six months, subject to performance targets and committee approval.
Key figures
- Base Salary
- 265000
- Exercise Price
- 1.05
- Bonus Target Percent
- 50
- Initial Option Grant
- 235000
- Subsequent Option Grant
- 235000
- Vesting Schedule
- 4 equal annual installments
- Change In Control Acceleration
- 100%
- Termination Without Cause Acceleration
- 50%
Price after filing
Close on the filing date to close N calendar days later (from $1.02). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.